FDA
-
-
-
-
-
-
-
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
-
-
-
-
-
-
-
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
-
-
-
-
-
-
-
TriSalus adds healthcare investor Stansky to board
-
-
-
-
-
-
-
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
-
-
-
-
-
-
-
TriSalus Life Sciences (TLSI) Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results
-
-
-
-
-
-
-
TriSalus Life Sciences (TLSI) Reports Prelim Q4 Results
-
-
-
-
-
-
-
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment
-
326,369 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

